Correlation between p53 over expression and response to bacillus calmette-guerin therapy in a high risk select population of patients with T1G3 bladder cancer

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 788-791

  Lebret, Thierry ^b   Becette, Véronique ^b   Barbagelatta, Michel ^b   Hervé, Jean Marie ^b   Gaudez, François ^b   Barré, Philippe ^b   Lugagne, Pierre Marie ^b   Botto, Henry ^a  

^a FOCH HOSPITAL   (France)

^b NONE

Author keywords

BCG vaccine; Bladder; Bladder neoplasms; Protein p53

Indexed keywords

BCG VACCINE; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYSTECTOMY; FEMALE; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0031950890     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63731-5     Document Type: Article

References (22)

1. Malmström, P. U., Bush, C. and Norlen, B. J.: Recurrence, progression and survival in bladder cancer. Scand. J. Urol. Nephrol., 21: 185, 1987.
2. Herr, H. W., Jaskse, G. and Scheinfeld, J.: The T1 bladder tumor. Sem. Urol., 8: 254, 1990.
3. Kavoussi, L. J., Torrence, R. J., Gillen, D. P., Hudson, M. A., Haaf, E. O., Dresner, S. M., Ratliff, T. L. and Catalona, W. J.: Result of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J. Urol., 139: 935, 1988.
4. Herr, H. W., Wartinger, D. D., Fair, W. R. and Oettgen, H. F.: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol., 147: 1020, 1992.
5. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Presinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. and Bos, J. L.: Genetic alterations during colorectal tumor development. New. Engl. J. Med., 319: 525, 1988.
6. Sidransky, D. and Messing, E.: Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes and growth factors. Urol. Clin. N. Amer., 19: 629, 1992.
7. Sidransky, D., Von Eschenbach, A. and Tsai, Y. C.: Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252: 706, 1991.
8. Lacombe, L., Dalbagni, G., Zhang, Z. F., Cordon-Cardo, C., Fair, W. R., Herr, H. W. and Reuter, V. E.: Overexpression of p53 protein in high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome. J. Clin. Oncol., 14: 2646, 1996.
9. Serth, J., Kuczyk, M. A. and Bokemeyer, C.: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Brit. J. Cancer, 71: 201, 1995.
10. Dalbagni, G., Saez, G. T., Oliva, M. R., Pellicer, A., Reuter, V. E., Fair, W. R. and Cordon-Cardo, C.: p53 mutation in bladder cancer: correlation between immunohistochemistry (IHC), single strand conformation polymorphism (SSCP) and sequencing. J. Urol., part 2, 149: 238A, abstract 98, 1993.
11. Kerns, B. J., Jordan, P. A., Moore, M. B., Humphrey, P. A., Berchuck, A., Kohler, M. F., Bast, R. C., Iglehart, J. D. and Marks, J. R.: p53 overexpression in formalin fixed, paraffin embedded tissue detected by immunohistochemistry. J. Histochem. Cytochem., 40: 1047, 1991.
12. Finlay, C. A., Hinds, P. W. and Levine, A. J.: The p53 protooncogene can act as a suppressor of transformation. Cell, 57: 1083, 1989.
13. Gibas, Z., Prout, G. R., Jr., Connolly, J. G., Pontes, J. E. and Sandberg, A. A.: Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res., 44: 1257, 1984.
14. Uchida, T., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kayema, T. and Koshiba, K.: p53 mutations and prognosis in bladder tumors. J. Urol., 153: 1097, 1995.
15. Olumi, A. F., Tsai, Y. C., Nichols, P. W., Skinner, D. G., Cain, D. R., Bender, L. I. and Jones, P. A.: Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res., 50: 7081, 1990.
16. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z. F., Sheinfeld, J., Herr, H. W. and Reuter, V. E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152: 388, 1994.
17. Serth, J., Kuczyk, M. A., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K. and Jonas, U.: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Brit. J. Cancer, 71: 201, 1995.
18. Habuchi, T., Ogawa, O., Kakehi, Y., Ogura, K., Koshiba, M., Sugiyama, T. and Yoshida, O.: Allelic loss of chromosome 17P in urothelial cancer: strong association with invasive phenotype. J. Urol., 148: 1595, 1992.
19. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
20. Ovesen, H., Horn, T. and Steven, K.: Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol., 157: 1655, 1997.
21. Yoshimura, I., Kudoh, J., Saito, S., Tazaki, H. and Shimizu, N.: p53 gene mutation in recurrent superficial bladder cancer. J. Urol., 153: 1711, 1995.
22. Pocock, R. D., Ponder, B. A. J., O'Sullivan, J. P. O., Ibrahim, S. K., Easton, D. F. and Shearer, R. J.: Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Brit. J. Urol., 54: 711, 1982.